Vlado Perkovic's Publications

Arnott C, Li JW, Cannon CP et alii
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

Conference Abstracts
2021
in Diabetes
Kalantar-Zadeh K, Jafar TH, Nitsch D et alii
Chronic kidney disease.

Journal articles
2021
Lancet
Jun M, Harris K, Heerspink HJL et alii
Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Journal articles
2021
Diabetes
Koomen JV, Stevens J, Bakris G et alii
Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Journal articles
2021
Clinical Pharmacology and Therapeutics
Perkovic V, Blackorby A, Cizman B et alii
MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS

Journal articles
2021
Nephrology Dialysis Transplantation
Perkovic V, Rovin B, Zhang H et alii
MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

Journal articles
2021
Nephrology Dialysis Transplantation
Wheeler DC, Weir M, Gogate J et alii
FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL

Journal articles
2021
Nephrology Dialysis Transplantation
Heerspink HJL, Oshima M, Zhang H et alii
Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.

Journal articles
2021
Am J Kidney Dis
Adler A, Agodoa L, Algra A et alii
Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Journal articles
2021
The Lancet
Zhou Z, Jardine MJ, Li Q et alii
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease Results from the CREDENCE Trial and Meta-Analysis

Journal articles
2021
Stroke
Yu J, Li J, Leaver PJ et alii
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

Journal articles
2021
Cardiovasc Res
Nataatmadja M, Krishnasamy R, Zuo L et alii
Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

Journal articles
2021
Kidney International Reports
Copland E, Canoy D, Nazarzadeh M et alii
Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Journal articles
2021
The Lancet Oncology
Oshima M, Jardine MJ, Agarwal R et alii
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Journal articles
2021
Kidney International
Yu J, Arnott C, Neuen BL et alii
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

Journal articles
2021
ESC Heart Failure
Singh AK, Blackorby A, Cizman B et alii
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.

Journal articles
2021
Nephrol Dial Transplant
Feng KY, Gogate J, Damaraju CV et alii
Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

Conference Papers
2021
in METABOLISM-CLINICAL AND EXPERIMENTAL
Evans RDR, Smyth B, Levin A et alii
The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

Journal articles
2021
Kidney International
Sarraju A, Li JW, Cannon CP et alii
Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Journal articles
2021
American Heart Journal
O'Hara DV, Parkhill TR, Badve SV et alii
The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

Journal articles
2021
Diabetes
Htay H, Bello AK, Levin A et alii
Hemodialysis Use and Practice Patterns: An International Survey Study

Journal articles
2021
American Journal of Kidney Diseases
Oshima M, Hara A, Toyama T et alii
Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

Journal articles
2021
Kidney International Reports
Koomen JV, Stevens J, Bakris G et alii
Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Journal articles
2021
Diabetes
Yu J, Zhou Z, Mahaffey KW et alii
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Journal articles
2021
International Journal of Cardiology
Neuen BL, Arnott C, Perkovic V et alii
Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Journal articles
2021
Diabetes
Mann JFE, Buse JB, Idorn T et alii
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

Journal articles
2021
Diabetes

Vlado Perkovic's Publications

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

Chronic kidney disease.

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Individual Atrasentan Exposure is Associated With Long-term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

MO559ASCEND-ND: STUDY DESIGN AND BASELINE CHARACTERISTICS

MO148A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LNP023 IN PRIMARY IGA NEPHROPATHY PATIENTS

FC 089EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR EVENTS BY BASELINE ALBUMINURIA: INTEGRATED ANALYSES FROM THE CANVAS PROGRAM AND CREDENCE TRIAL

Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease Results from the CREDENCE Trial and Meta-Analysis

Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.

Canagliflozin Reduces All-cause Hospitalization in Patients with Type 2 Diabetes Mellitus

The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

Hemodialysis Use and Practice Patterns: An International Survey Study

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes

Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis

The George Institute for Global Health

The George Institute country sites:

Acknowledgement of Country